Loss of dystrophin is associated to the increased myocardial stiffness in a model of left ventricular hypertrophy

DONATO M; BUCHHOLZ B; MORALES C; VALDEZ LB; ZAOBORNYJ T; BARATTA S; PAEZ D; MATOSO M; VACCARINO G; CHEJTMAN D; AGÜERO O; TELAYNA JM; NAVIA J; HITA A; BOVERIS A; GELPI RJ

MOLECULAR AND CELLULAR BIOCHEMISTRY

SPRINGER

Lugar: Berlin; Año: 2017

0300-8177

Transition from compensated to decompensated left ventricular hypertrophy (LVH) is accompanied by functional and structural changes. Here, the aim wasto evaluate dystrophin expression in murine models and human subjects with LVH by transverse aortic constriction (TAC) and aortic stenosis (AS), respectively. We determined whether doxycycline (Doxy) prevented dystrophin expression and myocardial stiffness in mice. Additionally, ventricular function recovery was evaluated in patients 1 year after surgery. Mice were subjected to TAC and monitored for 3 weeks. A second group received Doxy treatment after TAC. Patients with AS were stratified by normal left ventricular end-diastolic wall stress (LVEDWS) and high LVEDWS, and groups were compared. In mice, LVH decreased inotropism and increased myocardial stiffness associated with a dystrophin breakdown and a decreased mitochondrial O2 uptake (MitoMVO2). Thesealterations were attenuated by Doxy. Patients with high LVEDWS showed similar results to those observed in mice.A correlation between dystrophin and myocardial stiffness was observed in both mice and humans. Systolic function at 1 year post-surgery was only recovered in the normal- LVEDWS group. In summary, mice and humans present diastolic dysfunction associated with dystrophin degradation. The recovery of ventricular function was observed only in patients with normal LVEDWS and without dystrophindegradation. In mice, Doxy improved MitoMVO2.Based on our results it is concluded that the LVH with high LVEDWS is associated to a degradation of dystrophin and increase of myocardial stiffness. At least in a murine model these alterations were attenuated after the administration ofa matrix metalloprotease inhibitor.